Skip to main content

Cutaneous & COVID Derm Q&A

Melissa Weiss, Associate Editor
Jesse Veenstra, MD, PhD, discussed the findings from the recent Henry Ford Health System study on the risk of COVID-19 infection and severe outcomes among patients with immune-mediated inflammatory diseases treated with immunosuppressive therapies.
Melissa Weiss, Associate Editor
A new large-scale study is underway to assess the impact of systemic therapies on COVID-19 among patients with atopic dermatitis and psoriasis. Dr Emma Guttman discusses the goals of the study and how it could help shape COVID-19 treatment among patients with inflammatory skin diseases.
Melissa Weiss, Associate Editor
While the upper respiratory tract symptoms of the novel SARS-CoV-2 virus are widely recognized, new reports are suggesting possible skin manifestations among patients with the COVID-19. In an interview with The Dermatologist, Esther Freeman, MD, PhD, principle investigator, discussed the COVID-19 Dermatology registry in collaboration with the American Academy of Dermatology (AAD) and what the AAD hope to learn from providers across disciplines who are submitting cases.
Melissa Weiss, Associate Editor
As of March 27, 2020, the United States has become the epicenter of the coronavirus pandemic. Misha Rosenbach, MD, answered several questions regarding the current pandemic.
Back to Top